SecSonar.com

Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Viridian Therapeutics, Inc. (VRDN) is a Biotechnology company based in US with a market capitalization of $1.6B. Revenue grew 23359.9% year-over-year and free cash flow was negative at -$276.9M. This page tracks VRDN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 143 employees · IPO Jun 18, 2014

Valuation

Valuation & price

$16.82 · as of May 17, 2026 · -50.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.18

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$33.78$23.63$13.48Jul 25Dec 25Jul 26Jul 7, 25$15.89Jul 9, 25$17.04Jul 11, 25$17.04Jul 15, 25$16.26Jul 17, 25$17.05Jul 21, 25$16.79Jul 23, 25$17.95Jul 25, 25$17.28Jul 29, 25$16.79Jul 31, 25$17.52Aug 4, 25$16.86Aug 6, 25$17.20Aug 11, 25$16.89Aug 13, 25$18.85Aug 15, 25$18.54Aug 19, 25$17.81Aug 21, 25$18.02Aug 25, 25$18.57Aug 27, 25$18.56Aug 29, 25$18.38Sep 3, 25$19.47Sep 5, 25$18.72Sep 9, 25$20.21Sep 11, 25$19.65Sep 16, 25$18.66Sep 18, 25$19.62Sep 22, 25$19.55Sep 24, 25$19.50Sep 26, 25$20.19Sep 30, 25$21.58Oct 2, 25$21.22Oct 6, 25$20.83Oct 8, 25$21.36Oct 10, 25$20.99Oct 14, 25$20.78Oct 16, 25$23.01Oct 21, 25$24.02Oct 23, 25$22.07Oct 27, 25$22.54Oct 29, 25$23.01Oct 31, 25$23.63Nov 4, 25$22.55Nov 6, 25$27.50Nov 10, 25$27.65Nov 12, 25$28.94Nov 14, 25$28.77Nov 18, 25$28.59Nov 20, 25$29.47Nov 25, 25$31.41Nov 28, 25$31.96Dec 2, 25$30.43Dec 4, 25$32.46Dec 8, 25$31.88Dec 10, 25$32.60Dec 12, 25$32.31Dec 16, 25$32.85Dec 18, 25$31.60Dec 22, 25$32.47Dec 24, 25$32.28Dec 29, 25$31.54Jan 2, 26$30.68Jan 6, 26$30.72Jan 8, 26$30.33Jan 12, 26$32.57Jan 14, 26$33.78Jan 16, 26$33.26Jan 21, 26$32.29Jan 23, 26$32.93Jan 27, 26$33.54Jan 29, 26$33.57Feb 2, 26$33.20Feb 4, 26$30.37Feb 9, 26$29.60Feb 11, 26$30.07Feb 13, 26$27.90Feb 18, 26$28.11Feb 20, 26$27.44Feb 24, 26$29.40Feb 26, 26$29.49Mar 2, 26$30.25Mar 4, 26$30.39Mar 6, 26$28.34Mar 10, 26$29.19Mar 12, 26$28.41Mar 17, 26$28.60Mar 19, 26$27.84Mar 23, 26$27.62Mar 25, 26$28.35Mar 27, 26$27.39Mar 31, 26$19.56Apr 2, 26$18.84Apr 7, 26$13.96Apr 9, 26$15.38Apr 13, 26$14.80Apr 15, 26$14.88Apr 17, 26$14.80Apr 22, 26$14.33Apr 24, 26$13.73Apr 28, 26$13.61Apr 30, 26$13.48May 4, 26$14.06May 6, 26$17.53May 8, 26$16.61May 12, 26$16.86May 14, 26$17.43May 18, 26$16.10May 20, 26$17.63May 22, 26$17.24May 28, 26$17.45Jun 1, 26$16.96Jun 3, 26$16.35Jun 5, 26$15.78Jun 9, 26$16.31Jun 11, 26$16.14Jun 15, 26$16.30Jun 17, 26$16.71Jun 22, 26$17.63Jun 24, 26$17.32Jun 26, 26$17.90Jul 2, 26$19.40
$13.3052-week range$33.78
Loading valuation history…

Fundamentals

Key fundamentals

$1.6B

Market cap

23359.9%

Revenue growth (YoY)

100.0%

Gross margin

-$276.9M

Free cash flow (USD)

-$824M

Net debt

Net cash position

24.9%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$3.3MFY 2017$4.0MFY 2018$8.4MFY 2019$4.5MFY 2020$1.1MFY 2021$3.0MFY 2022$1.8MFY 2023$314.0KFY 2024$302.0KFY 2025$70.8M
$3.3M$70.8M

Free cash flow by year

2016 → 2025

FY 2016$-7.2MFY 2017$-28.4MFY 2018$-27.3MFY 2019$-36.1MFY 2020$-29.8MFY 2021$-54.9MFY 2022$-94.6MFY 2023$-185.1MFY 2024$-232.8MFY 2025$-276.9M
-$7.2M-$276.9M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

1

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventFDA ApprovalJun 26, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 3, 2026Filing
  • 8-K eventDebt RefinancingMay 28, 2026Filing
  • 8-K eventCommercial Manufacturing AgreementMay 26, 2026Filing
  • Insider buyInsider Buy $20.0MFairmount Funds Management LLC · Director, 10% Owner · $20MMay 13, 2026Filing
  • 8-K eventConvertible Notes IssuedMay 11, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing
  • 8-K eventCorporate PresentationMay 5, 2026Filing

Questions

Frequently asked questions

What is Viridian Therapeutics, Inc.'s market cap?

Viridian Therapeutics, Inc. (VRDN) has a market capitalization of $1.6B.

What is VRDN's P/E ratio?

A meaningful P/E ratio is not available for VRDN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is VRDN's price-to-book (P/B) ratio?

VRDN trades at 2.18 times book value per share.

Are insiders buying VRDN stock?

Yes — SEC Form 4 filings show 1 open-market insider buy and 0 sells at Viridian Therapeutics, Inc. in the last 90 days.

Same arena

Related companies in Biotechnology

NTLA

Intellia Therapeutics, Inc.

$1.6B

INVA

Innoviva, Inc.

$1.6B

RXRX

Recursion Pharmaceuticals, Inc.

$1.6B

NRIX

Nurix Therapeutics, Inc.

$1.5B

VIR

Vir Biotechnology, Inc.

$1.6B

IMTX

Immatics N.V.

$1.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.